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SurgeryRefractory epilepsy is a rare, long-term complication in children with acute leukemia who are receiving che-
motherapy. A few studies have reported cases of several patients who developed recurrent complex partial
seizures after the initiation of chemotherapy. In these cases, the cause of the refractory seizures was identi-
ﬁed as mesial temporal lobe sclerosis. Here, we report on two patients with extratemporal lesions accompa-
nied by refractory seizures, a long-term complication of acute lymphocytic leukemia. Using presurgical
evaluations and measures of the surgical outcomes, the lesions were identiﬁed as epileptogenic and were lo-
cated in the mesial temporal lobe. The underlying pathophysiological background is discussed to aid in un-
derstanding this uncommon long-term complication.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Epileptic seizures are a complication of chemotherapy in children
diagnosed with acute leukemia. Epilepsy develops in 10% to 13% of
children with acute lymphocytic leukemia (ALL) [1,2]. However, medic-
ally refractory epilepsy as a late complication has rarely been reported,
and the mechanism of intractable seizures after chemotherapy in
children with leukemia has not been clearly explained. We present two
pediatric patients with ALLwho developedmedically refractory epilepsy
following chemotherapy. These two patients were diagnosed with tem-
poral ‘plus’ epilepsies andwere successfully treated by surgical resection
of the epileptogenic zone. The underlying pathophysiological back-
ground and the treatment for this complication are discussed.2. Case 1
A 10-year-old boy was admitted to the hospital with pre-B acute
lymphocytic leukemia. He received CVDLP (cyclophosphamide, vincris-
tine, daunomycine, L-asparaginase, prednisone) and achieved complete
remission after one cycle of chemotherapy. However, coagulation
abnormalities were detected with the third dose of L-asparaginase. He
developed cerebral dysfunction with confusion and convulsions. He
was diagnosed with a cerebral parenchymal hemorrhage of the leftn).
Inc.Open access under CC BY license.parietal–occipital lobe and an epidural hemorrhage of the left occipital
region using a cranial computed tomography (CT) scan. After a plasma
transfusion, the hemorrhage was gradually absorbed. He then received
an intrathecal injection of MTX (methotrexate) and Ara-c (cytarabine).
Next, the patientwas alternately treatedwithVM26 (teniposide), Ara-c,
HD-MTX (high dose methotrexate), and VDLP (vincristine, daunorubi-
cin, L-asparaginase, prednisone).
Four years after the discontinuation of the antileukemic treatment,
the patient had his ﬁrst epileptic seizure. From then on, he experienced
stereotyped seizures that lasted 2 to 3 min. The seizures were preceded
by an aura that the patient described as a feeling of needing to urinate.
During the seizures, the patient sat up and purposelessly moved his
body, including movements of oral automatism, eye blinks, and tonic
and clonic movements of his right face and right limbs. The seizures
mostly occurred during sleep but occasionally occurred during the day-
time. Several antiepileptic drugs, including topiramate, clonazepam,
phenytoin sodium, carbamazepine, lamotrigine, and sodium valproate,
were administered in the following years, but the outcome was always
disappointing. When hewas admitted to the hospital, his seizures were
occurring several times per week. Interictal scalp electroencephalogra-
phy (EEG) recordings revealed left temporal–occipital discharges, and
long-term video-EEG monitoring revealed that the seizures originated
from the same region. Magnetic resonance imaging (MRI) scans showed
slight atrophy of the cortex in this region (Fig. 1). Long-term intracranial
recording was performed to localize the epileptogenic focus and to
more accurately map the functional cortex (Fig. 2). The interictal cortical
EEG showed repeated spikes in the left temporal lobe, especially in the
posterior temporal region. The ictal EEG showed that the seizures pre-
dominantly originated from the posterior part of the temporal lobe. Surgi-
cal excision of the epileptogenic tissue in the left temporal–parietal region
Fig. 1. Slight atrophy of the cortex in the left temporal–parietal region.
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months. However, the seizures gradually reappeared two months after
the operation. Six months later, after further preoperative evaluation, an
additional resection was performed to remove the left anterior temporal
lobe (4 cm in length), including 2 cm of the hippocampus. Since the
operation, the patient has been seizure-free for over one year and is
medicatedwith carbamazepine and lamotrigine. Postoperativehistopath-
ological examination revealed cicatrix and gliosis in the resected posterior
temporal tissue (ﬁrst resection) and neuronal loss and gliosis in the
hippocampus (second resection).
3. Case 2
A 3-year-old boy was admitted to the hospital with ALL (L1). He
received DVLP (daunomycine, vincristine, L-asparaginase, prednisone)
and achieved complete remission after one cycle of treatment. However,Fig. 2. Cortical electrodes were implanted.he developed recurrent seizures approximately onemonth after his ﬁnal
chemotherapy cycle. An MRI scan showed inﬁltrated lesions in his brain
(Fig. 3). At that time, he received a chemotherapy protocol of VM26,
Ara-c, HD-MTX, and VDLP. His seizures gradually decreased and ﬁnally
disappeared with elimination of the lesions and effective chemotherapy
without antiepileptic drugs. However, his seizures reoccurred and in-
creased in frequency two years later. Sometimes the seizures occurred
after an aura of abdominal discomfort. During the seizures, the patient
had automatisms of his right hand and arm and then displayed tonic
and clonic movements in his left face and left limbs. The seizures gradu-
ally failed to respond to antiepileptic drugs, including topiramate, carba-
mazepine, sodium valproate, and oxcarbazepine, over the following
years. The frequency of his seizures ranged from 20 times/day to once
a week.
His medically refractory epilepsy was surgically evaluated when
he was ﬁfteen years old. Interictal scalp EEG recordings revealed
right temporal–parietal discharges, and long-term video-EEG moni-
toring revealed that the seizures originated from the same region.
Magnetic resonance imaging scans also showed hippocampal sclero-
sis on the right side, in addition to the lesion in the right temporal–
parietal region (Figs. 4 and 5). Furthermore, the spike dipoles of the
magnetoencephalogramwere concentrated around the lesion. Therefore,
the epileptogenic zone (EZ) was localized in the region of the posterior
temporal-parietal lobe. Surgical resection was performed. The resection
includedboth the hippocampus and theposterior temporal lesion. A post-
operative histopathological examination revealed severe hippocampal
sclerosis and cicatrix gyrus in the resected temporal–parietal tissue. The
patient has been seizure-free in the year following the operation and
uses the medication oxcarbazepine.
4. Discussion
Although epileptic seizures are relatively common in children
with acute leukemia, refractory seizures are rare. A few studies have
reported several cases of recurrent complex partial seizures (CPSs)
that developed after the initiation of chemotherapy. Goyal described
three children with acute leukemia who developed refractory CPSs
after chemotherapy and cranial irradiation [3]. Additionally, Faraci
reported on the cases of three childrenwhounderwent allogenic hema-
topoietic stem cell transplantation with cyclosporin-A and developedFig. 3. Inﬁltrated lesions in the right parietal and left frontal lobes.
Fig. 4. Lesions in the right posterior temporal–parietal region.
Fig. 5. Mesial temporal lobe sclerosis in the right temporal lobe.
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The reason for the repeated seizures in all of these patients was identiﬁed
as mesial temporal lobe sclerosis (MTS). Various factors play a role in the
development of MTS. Diffuse cerebral atrophy, leukoencephalopathy,
central pontine myelinolysis, leukemic inﬁltration via the arachnoids,
and microangiopathy are related to the primary effects of the disease
and/or the treatment [5–9]. The use of chemotherapeutic agents, such
as systemic vincristine, L-asparaginase, systemic or intrathecal metho-
trexate, and cytosine arabinoside might result in disturbances of brain
metabolism and the vascular system. Furthermore, the use of cranial
radiotherapy could cause white matter destruction, vascular damage
leading to hemorrhage and calciﬁcation, and enlargement of the ventri-
cles and/or sulci [10–12].
However, the two patients described in this report were diagnosed
with temporal plus epilepsy rather than with classical temporal lobe
epilepsy [13]. The focal extratemporal cortex was involved in the EZs
located next to the sclerosis in the mesial temporal lobe. The underlying
pathophysiological background of this complication was worthy of
discussion to explore the mechanisms of the development of refractory
epilepsy.
In the ﬁrst patient, the hematoma that presented after chemothera-
py damaged some areas of the focal cortex, which was veriﬁed by the
neuronal loss and ﬁbrous gliosis observed in the histopathological
exam. The scar lesionmay have altered the balance of excitation and in-
hibition in the cortex in the years following chemotherapy and may be
the origination point of the seizures. However, the predominate reason
for medically resistant seizures may be secondary MTS because only
when the mesial temporal lobe was removed by the second operation
was the patient continuously seizure-free. In the second patient, all
the evaluations identiﬁed the posterior temporal–parietal lesion as
epileptogenic, in addition to the patient having MTS.
Medically refractory epilepsy should be considered as a potential
late complication in children with acute leukemia who are receiving
chemotherapy. Any focal damage caused by the leukemic infusion, che-
motherapy, radiotherapy, or viral infection might contribute to the
development of long-term seizure events. The cortical lesions and the
mesial temporal lobe should be examined in follow-up visits. Repeated
EEG monitoring might be helpful for some of these patients in pre-
dicting the possibility of recurrent seizures. Furthermore, to our limitedknowledge, surgery is a potential treatment for some patients with
medically refractory epilepsy. Although it is more difﬁcult to localize
the epileptogenic zone in patients with temporal ‘plus’ epilepsies, per-
fect outcomes could be expected after carefully planned operations [14].
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